Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
ARWR · Nasdaq · United States · Pharmaceutical Preparations
In shortARROWHEAD PHARMACEUTICALS, INC. is loss-making, generates cash and holds more cash than debt, with revenue growing (+23,258.2% last year).
Financial health
Mixed
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 11.9% | 56/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -0.2% | 19/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -0.5% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 12.3% | 82/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.86× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 1.10× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.76 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 18.9% | 96/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 10397.8% | 0/100 |
| Operating margin volatility | 7541.7% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 50.5% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 138 | 243 | 241 | 3.6 | 829 |
| Research & development | 206 | 297 | 353 | 506 | 607 |
| Operating income | (149) | (179) | (205) | (601) | 98 |
| Interest expense | 0 | 0 | 18 | 32 | 89 |
| Pre-tax income | (141) | (173) | (206) | (612) | 52 |
| Income tax | 0 | 3.8 | 2.8 | (2.8) | 21 |
| Net income | (141) | (176) | (205) | (599) | (1.6) |
| Diluted EPS | −$1.36 | −$1.67 | −$1.92 | −$5.00 | −$0.01 |
| Diluted shares (millions) | 104 | 105 | 107 | 120 | 134 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
0.76 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Aug 4, 2026